$DRTSW

Alpha Tau Medical Ltd.

CIK:0001871321|SEC Filings

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Income Statement [Abstract]
Research and development, net	$ 32,065	$ 27,020	$ 26,424
Marketing expenses	1,860	2,349	1,924
General and administrative	8,363	6,673	7,332
Total operating loss	42,288	36,042	35,680
Financial (income) expenses, net	218	(4,298)	(6,539)
Loss before taxes on income	42,506	31,744	29,141
Tax on income	121	6	16
Net loss	42,627	31,750	29,157
Net comprehensive loss	$ 42,627	$ 31,750	$ 29,157
Net loss per share, basic (in Dollars per share)	$ (0.53)	$ (0.45)	$ (0.42)
Net loss per share, diluted (in Dollars per share)	$ (0.53)	$ (0.45)	$ (0.42)
Weighted-average shares used in computing net loss per share, basic (in Shares)	80,581,440	69,927,566	69,377,922
Weighted-average shares used in computing net loss per share, diluted (in Shares)	80,581,440	69,927,566	69,377,922

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net loss	$ (42,627)	$ (31,750)	$ (29,157)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	1,232	1,102	1,074
Loss from property and equipment disposals	35
Share-based compensation	10,617	9,916	7,926
Non-cash financial expenses (income), net	(245)	40	1,740
Decrease (increase) in prepaid expenses and other receivables	(21)	(558)	281
(Increase) decrease in long-term prepaid expenses	(47)	39	(80)
Change in the fair value of warrants liabilities	2,016	(259)	(2,033)
Increase in trade payables	337	965	1,143
Increase in other payables and accrued expenses	1,131	659	1,228
Increase in deferred taxes liability	97
Change in operating lease liabilities	(23)	(726)	(809)
Change in operating lease right-of-use assets	817	789	729
Net cash used in operating activities	(26,681)	(19,783)	(17,958)
Cash flows from investing activities:
Investment in short-term deposits	(70,490)	(125,082)	(163,629)
Investment in restricted deposit		(103)	(3,152)
Proceeds from short-term deposits	55,977	148,191	191,864
Purchase of property and equipment	(6,075)	(2,238)	(6,401)
Net cash provided by (used in) investing activities	(20,588)	20,768	18,682
Cash flows from financing activities:
Proceed from short-term loan	5,152
Repayment of short-term loan	(5,152)
Proceeds from long-term loan			5,248
Proceeds from issuance of Ordinary shares, net	45,496
Proceeds from exercise of options	272	25	49
Net cash provided by financing activities	45,768	25	5,297
Effect of exchange rate changes on cash and cash equivalents	(21)	57	(50)
Increase (decrease) in cash and cash equivalents	(1,522)	1,067	5,971
Cash and cash equivalents at the beginning of the year	13,724	12,657	6,686
Cash and cash equivalents at the end of the year	12,202	13,724	12,657
Supplemental disclosure of cash flows information:
Income taxes paid	4	5	16
Interest received	2,780	4,424	6,160
Interest paid	381	321	52
Supplemental disclosure of noncash investing and financing activities:
Operating lease liabilities arising from obtaining right of use assets	422	35	3,304
Purchases of property and equipment in exchange for Ordinary shares	675
Purchases of property and equipment in other payables and accrued expenses	$ 244

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
CURRENT ASSETS:
Cash and cash equivalents	$ 12,202	$ 13,724
Short-term deposits	60,924	45,876
Restricted deposits	3,777	3,255
Prepaid expenses and other receivables	1,395	1,374
Total current assets	78,298	64,229
LONG-TERM ASSETS:
Long-term prepaid expenses	479	432
Property and equipment, net	19,661	13,934
Operating lease right-of-use assets	7,214	7,609
Total long-term assets	27,354	21,975
Total assets	105,652	86,204
CURRENT LIABILITIES:
Trade payables	3,868	3,531
Other payables and accrued expenses	5,508	4,133
Current maturities of operating lease liabilities	1,131	1,011
Total current liabilities	10,507	8,675
LONG-TERM LIABILITIES:
Long-term loan	6,352	5,561
Warrants liability	5,354	3,338
Operating lease liabilities	6,243	5,964
Deferred tax liability	97
Total long-term liabilities	18,046	14,863
Total liabilities	28,553	23,538
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS’ EQUITY:
Ordinary shares of no-par value per share – Authorized: 362,116,800 shares as of December 31, 2024 and 2025; Issued and outstanding: 70,380,570 and 88,009,737 shares as of December 31, 2024 and 2025, respectively
Additional paid-in capital	267,235	210,175
Accumulated deficit	(190,136)	(147,509)
Total shareholders’ equity	77,099	62,666
Total liabilities and shareholders’ equity	$ 105,652	$ 86,204